Key Takeaways

  • Iofina produced 393.3 metric tonnes of crystalline iodine in H1 2026, a 29% jump on the 305.5 tonnes achieved in the same period of 2025, and ahead of its raised 385-tonne guidance.
  • IO#12, set to become the company's largest IOsorb plant, is on track to be commissioned during Q3 2026, with production expected to begin towards the end of September and annual capacity of 170-220 tonnes.
  • Second-half guidance stands at 460-485 tonnes, pointing to another record full year on top of 2025's 743-tonne haul.
  • Spot iodine continues to trade in the mid-US$70 per kilogram range, underpinning margins as Iofina scales towards a long-term ambition of 2,000 tonnes a year.
  • The group is finalising a US$10 million project Loan Facility with its existing lender to help fund the expansion pipeline.

Iofina plc (LSE:IOF) is a small-cap producer that has built a reputation as one of the few Western companies able to grow iodine Supply from scratch. The element is a strategic input for X-ray contrast media, LCD polarising film, animal feed and a widening range of specialty chemicals, yet global supply is concentrated in Chile and Japan. Iofina's edge is its proprietary WET IOsorb technology, which extracts iodine from the brine co-produced by oil and gas wells in the United States. That brine would otherwise be waste; Iofina turns it into a saleable Commodity through five producing plants in Oklahoma, then upgrades much of the raw iodine into higher-value compounds through its Iofina Chemical arm. Incorporated in 2005 and admitted to AIM in May 2008, the group is now the second-largest iodine producer in North America. Its H1 2026 corporate update, released on 15 July, confirmed that the growth story has stepped up another gear.

Latest Company Development

The headline figure from the update is a first-half production record. Iofina made 393.3 metric tonnes of crystalline iodine in the six months to 30 June 2026, a 29% increase on the 305.5 tonnes produced in H1 2025. Crucially, the number beat the company's own upgraded guidance of around 385 tonnes, itself raised earlier in the year after a strong first quarter delivered 178.9 tonnes. Management attributed the outperformance to higher brine volumes flowing through its central Oklahoma facilities.

The forward-looking element of the announcement is arguably more significant than the record itself. Iofina confirmed that IO#12, a plant located in the Permian Basin, remains on track for commissioning during the third quarter of 2026, with production expected to commence towards the end of September. Once fully operational, IO#12 is expected to become the company's largest IOsorb plant, contributing 170-220 tonnes of crystalline iodine annually. That single facility would therefore add materially to a group that produced 743 tonnes across the whole of 2025. Alongside IO#12, the company said IO#11 is receiving additional brine capacity via a partner pipeline, which is expected to become operational within the same quarter. In short, the two developments that should drive Iofina's output through the back half of 2026 are both scheduled to arrive within weeks.

Financial and Operational Position

Iofina enters this expansion phase from a position of genuine financial strength, a marked change from its more precarious past. Full-year 2025 results showed Revenue of US$66.5 million, up 22%, with Gross Profit of US$18 million (up 36%) and adjusted EBITDA of US$11.8 million, a 56% increase. Full-year iodine production of 743 tonnes was 17% higher, while sales volumes surged 42% — the eighth consecutive year of growth. The Balance Sheet closed the year with US$11.7 million of cash and net cash of US$5.2 million, after US$8.4 million of Investment in new plants and chemical processing capability.

Underpinning this is a supportive pricing backdrop. In the H1 2026 update Iofina noted that spot iodine prices continue to trade in the mid-US$70 per kilogram range on a 100% basis, a level that has held firm amid tight global supply. With production rising and prices elevated, Operating Leverage is pronounced — each incremental tonne is highly cash-generative. To fund the next leg of growth, Iofina said it was finalising documentation on a US$10 million project loan facility with its existing lender, preserving balance-sheet flexibility while several plants come on stream at once.

What Could Drive the Shares Next

The most immediate catalyst is the successful commissioning of IO#12. A clean, on-time start-up towards the end of September would validate management's execution and de-risk the second-half guidance of 460-485 tonnes. Delivering that range would take full-year 2026 output comfortably above 850 tonnes, another record. Beyond the near term, the company has articulated a long-term target of 2,000 tonnes of annual iodine production — roughly a tripling from current levels — which, if credibly progressed, could reframe how the market values the business. Continued firmness in the iodine price, and evident Demand from the animal health and animal feed end-markets that Iofina serves, would add further support. For a company of this size, consistent delivery against stated milestones is often the single biggest driver of a re-rating.

Risks Investors Should Watch

The bull case rests on several assumptions that could disappoint. Iofina's feedstock is brine from third-party oil and gas operations, so its output is tied to drilling activity and pipeline arrangements it does not fully control. New-plant commissioning carries execution risk: ramp-ups can slip, and IO#12's contribution to 2026 depends on a start-up in the final days of the quarter. The iodine price, while strong today, has been volatile historically; a Reversal would compress margins. As an AIM-listed micro-cap, the shares can be Illiquid and sentiment-driven, and the new US$10 million loan facility, though modest, adds fixed obligations during heavy Capital spending. None of these are unusual for a growth-stage resources company, but all Warrant attention.

Outlook

The trajectory Iofina has laid out for the remainder of 2026 is unusually clear for a company of its scale. With a record first half banked, two new sources of capacity due within the current quarter, and a firm iodine price, the building blocks for another record year are in place. The 460-485 tonne second-half guidance implies momentum carrying into 2027, and the 2,000-tonne long-term goal gives investors a sense of the runway. Delivery, as ever, is the operative word.

Final Take

Iofina's H1 2026 update confirms both a genuine operational record and a credible next catalyst. A 29% jump in first-half production, achieved ahead of upgraded guidance, shows the existing fleet is performing; the imminent start-up of IO#12 offers a step-change in scale. Backed by a net cash balance sheet, strong margins and a supportive commodity price, the company looks better placed than at any point in its history — provided the new plant delivers on schedule.